BRIEF: XtalPi shares surge on Microsoft China partnership
AI pharmaceutical company XtalPi Holdings Ltd. (2228.HK) on Monday announced it has entered into a strategic cooperation memorandum with Microsoft China for new drug and materials development. Under the tie-up, the…
‘Warcraft’ return to NetEase signals extension of China’s gaming relaxation
A new deal to bring popular ‘World of Warcraft’ games back to China after a one-year absence will have relatively little financial impact on the game’s local host Key Takeaways:…
Not quite closure: Alibaba exit leaves questions for SenseTime
Investors have been cashing out of the Chinese AI specialist while other AI stocks around the world are surging Key Takeaways: SenseTime’s battered share price enjoyed a brief bounce after…
CHINA BULLETIN: High-Level China-U.S. Exchanges Pick Up
In this week’s issue U.S.-China exchanges pick up, supermarket sales slump, and AI attacks AI. On a scale of 1 to 100, we give the week a 40 for offshore-listed China stocks.
Feeling the Love: Chinese Tech Giants Catch ChatGPT Fever
ChatGPT, an AI-driven chatbot that is the talk of the tech world, could shake up internet searching and other types of online businessKey Takeaways:The global buzz around ChatGPT has spread…
FAST NEWS: Megvii Technology Chief Scientist Dead at 45
The latest: Sun Jian, the chief scientist and managing director of research at top China artificial intelligence (AI) company Megvii Technology Ltd., died at the age of 45 on June 14,…
21Vianet Moving to Margins of Data Center Universe?
Microsoft’s China cloud services partner reports slowest revenue growth in first quarter among the country’s three major independent data center operators Key takeaways: 21Vianet’s latest results show it’s the slowest-growing…
Recent Articles
RECENT ARTICLES
-
NEWS WRAP: Surging Xtalpi seizes on tech rally to raise $267 million
2228.HK - Yunji rides robotics wave to Hong Kong IPO with A-list of backers
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
- Cancer drug maker Genfleet joins Hong Kong IPO influx
